Companies › GYRE

GYRE THERAPEUTICS INC (GYRE)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001124105 · EDGAR filings · Updated 2026-07-16

GYRE THERAPEUTICS INC (GYRE) has reported institutional ownership of 3.5%, with 56 institutional managers holding positions valued at $23.8M per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.

Latest updates

• 2026-07-16 — Current report (8-K) filed
• 2026-07-15 — Amended current report (8-K/A) filed
• 2026-07-13 — S-3/A filed
• 2026-06-30 — Insider transaction reported (Form 4)
• 2026-06-30 — Insider transaction reported (Form 4)
• 2026-06-30 — Insider transaction reported (Form 4)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, GYRE THERAPEUTICS INC has 56 institutional holders and institutional ownership of 3.5%.

Insider activity

Insiders reported 17 transactions (0 buys, 12 sells) across 3 reporting insiders, with a net reported value of −$204.4K.

Data flags from SEC filings

Related companies

VERRICA PHARMACEUTICALS INC (VRCA) · LIPOCINE INC NEW (LPCN) · TELIX PHARMACEUTICAL LTD (TLX) · GENELUX CORPORATION (GNLX) · INOTIV INC (NOTVQ) · FILANA THERAPEUTICS INC (FLNA)